STAAR Surgical names Warren Foust CEO, Andrews to EVP and CFO
STAAR Surgical (NASDAQ:STAA) said its board appointed Warren Foust as President and CEO effective immediately, and named Deborah Andrews EVP while keeping her as CFO. Foust joined in 2023 and most recently served as President and COO since March 2025. Andrews has been interim Co-CEO since February 2026. The company cited a global search for permanent leadership.
How this was made
The 30-second read
Why it matters
The effective-date executive appointments can influence near-term expectations for strategy, capital allocation, and reporting cadence, but the article does not provide new guidance, trial results, or financial metrics.
Market read
This is a governance and execution catalyst for STAAR, with potential sentiment impact but no new quantitative fundamentals in the text.
What to watch
Investors will likely focus on whether the CFO role remains with Andrews and whether Foust’s prior surgical-vision background changes priorities for lens pipeline, manufacturing scale, or commercial expansion.
Background
STAAR says it conducted an extensive global search for permanent leadership; Foust joined in 2023 and has been COO since 2025, while Andrews has served as interim co-CEO and CFO since 2025.
Ticker impact
STAAR Surgical appointed Warren Foust as President and CEO and named Deborah Andrews EVP and CFO effective today, reshaping leadership and oversight.
Likely modest, two-sided reaction as investors assess continuity versus strategic change; follow-through depends on any future guidance or product updates.
The disclosure is a concrete executive change with effective date, but it lacks new numbers, contracts, regulatory decisions, or clinical/product milestones that would directly re-rate fundamentals.
Market effects
Could marginally affect sentiment around ophthalmic implant makers if investors interpret the CEO/CFO reshuffle as improving execution discipline.
Limited, company-specific impact with no stated regional macro linkage.
Low; the article does not cite global regulatory actions, supply disruptions, or international contract wins.
Counterpoint
Because both executives are long-tenured internally, the market may already have priced much of the transition risk, making the incremental impact smaller than typical CEO-change stories.
Key entities
- public_companySTAAR Surgical Company
Appointed Warren Foust as President and CEO and named Deborah Andrews EVP and CFO effective today.
- executiveWarren Foust
Joined STAAR in April 2023; promoted to President and CEO effective today.
- executiveDeborah Andrews
Continues as CFO and becomes EVP effective today after serving as interim co-CEO.
